Dr Reddy’s Laboratories on Tuesday announced that it has launched Sorafenib tablets, used in the treatment of various cancers, in the US market after getting approval from the US Food and Drug Administration (USFDA).
“We are pleased to launch this important generic product, illustrating our continued commitment to bringing affordable generic medicines to market for patients,” Dr Reddy’s Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
Dr. Reddy’s Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120 and are used in the treatment of liver, kidney and thyroid cancer.
According to a report by news agency PTI, the company’s product is a therapeutic generic equivalent of Bayer HealthCare Pharmaceuticals Inc’s Nexavar tablets.
Sorafenib which belongs to a class of medications called kinase inhibitors works by blocking the action of an abnormal protein that signals cancer cells to multiply. The drug helps stop the spread of cancer cells.is used to treat kidney, liver, and thyroid cancer.
(With inputs from PTI)